December 2025 USAntibiotics expanded domestic manufacturing capacity for Augmentin XR following its FDA approval, supporting a more resilient supply chain for essential antibiotics used to treat severe bacterial infections.
June 2025 USAntibiotics received U.S. FDA approval for domestically manufactured Augmentin XR (amoxicillin/clavulanate potassium) under the FDA's Commissioner's National Priority Voucher program. The approval strengthens the U.S. supply of a key broad-spectrum antibiotic commonly used in the management of deep neck infections, including retropharyngeal abscesses.